Drug development in neuropsychopharmacology.
Personalized medicine is still in its infancy concerning drug development in neuropsychopharmacology. Adequate biomarkers with clinical relevance to drug response and/or tolerability and safety largely remain to be identified. Possibly, this kind of personalized medicine will first gain clinical relevance in the dementias. The clinical relevance of the genotyping of drug-metabolizing enzymes as suggested by drug licensing authorities for the pharmacokinetic evaluation of medicinal products needs to be proven in sound clinical trials.
Fritze
Jürgen
J
Medical Affairs, German Association of Private Health Insurers, Bayenthalgürtel 26, Köln, Germany. juergen.fritze@dgn.de
D015415:Biomarkers; D006801:Humans; D001523:Mental Disorders / Q000188:drug therapy* / Q000235:genetics*; D009480:Neuropharmacology; D011600:Psychopharmacology; D011619:Psychotropic Drugs / Q000493:pharmacokinetics / Q000494:pharmacology
D015415:Biomarkers; D011619:Psychotropic Drugs